Eptifibatide-induced acute profound thrombocytopenia: A case report
<h3>Rationale</h3><p dir="ltr">Eptifibatide is an antiplatelet agent used in the medical management of acute coronary syndrome. Although multiple studies did not reveal a significant association between eptifibatide and the development of thrombocytopenia, recent case rep...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513548300845056 |
|---|---|
| author | Mohammed A. Alamin (14182297) |
| author2 | Abdulrahman Al-Mashdali (16388474) Dawoud I. Al Kindi (17191426) Elkhansa A. Elshaikh (21348560) Fahmi Othman (14777506) |
| author2_role | author author author author |
| author_facet | Mohammed A. Alamin (14182297) Abdulrahman Al-Mashdali (16388474) Dawoud I. Al Kindi (17191426) Elkhansa A. Elshaikh (21348560) Fahmi Othman (14777506) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohammed A. Alamin (14182297) Abdulrahman Al-Mashdali (16388474) Dawoud I. Al Kindi (17191426) Elkhansa A. Elshaikh (21348560) Fahmi Othman (14777506) |
| dc.date.none.fl_str_mv | 2022-10-21T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1097/md.0000000000028243 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Eptifibatide-induced_acute_profound_thrombocytopenia_A_case_report/29046263 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences acute coronary syndrome drug-induced thrombocytopenia eptifibatide glycoprotein IIa/IIIb inhibitors thrombocytopenia |
| dc.title.none.fl_str_mv | Eptifibatide-induced acute profound thrombocytopenia: A case report |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Rationale</h3><p dir="ltr">Eptifibatide is an antiplatelet agent used in the medical management of acute coronary syndrome. Although multiple studies did not reveal a significant association between eptifibatide and the development of thrombocytopenia, recent case reports brought attention to this relatively rare side effect.</p><h3>Patient concerns</h3><p dir="ltr">We report a 61 years old male with acute coronary syndrome who underwent primary coronary intervention.</p><h3>Diagnosis and intervention</h3><p dir="ltr">The patient developed acute profound thrombocytopenia following eptifibatide administration. Following prompt offending drug discontinuation, the platelet counts recovered, without clinical sequelae or the need for platelet transfusion. Dual antiplatelet therapy with aspirin and clopidogrel was resumed after platelet count normalization.</p><h3>Outcomes</h3><p dir="ltr">The patient had a normal platelet count and no bleeding events on follow-up after three months upon discharge.</p><h3>Conclusion</h3><p dir="ltr">Eptifibatide, a glycoprotein IIa/IIIb inhibitor used in the management of acute coronary syndrome, can induce acute, profound thrombocytopenia that can have significant morbidity in patients. This case highlights this relatively rare side effect and the importance of monitoring blood counts and observing for any signs of bleeding or thrombosis that might occur in such patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1097/md.0000000000028243" target="_blank">https://dx.doi.org/10.1097/md.0000000000028243</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_0ec978708f3302ff73b9b0128d7d1171 |
| identifier_str_mv | 10.1097/md.0000000000028243 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29046263 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Eptifibatide-induced acute profound thrombocytopenia: A case reportMohammed A. Alamin (14182297)Abdulrahman Al-Mashdali (16388474)Dawoud I. Al Kindi (17191426)Elkhansa A. Elshaikh (21348560)Fahmi Othman (14777506)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesacute coronary syndromedrug-induced thrombocytopeniaeptifibatideglycoprotein IIa/IIIb inhibitorsthrombocytopenia<h3>Rationale</h3><p dir="ltr">Eptifibatide is an antiplatelet agent used in the medical management of acute coronary syndrome. Although multiple studies did not reveal a significant association between eptifibatide and the development of thrombocytopenia, recent case reports brought attention to this relatively rare side effect.</p><h3>Patient concerns</h3><p dir="ltr">We report a 61 years old male with acute coronary syndrome who underwent primary coronary intervention.</p><h3>Diagnosis and intervention</h3><p dir="ltr">The patient developed acute profound thrombocytopenia following eptifibatide administration. Following prompt offending drug discontinuation, the platelet counts recovered, without clinical sequelae or the need for platelet transfusion. Dual antiplatelet therapy with aspirin and clopidogrel was resumed after platelet count normalization.</p><h3>Outcomes</h3><p dir="ltr">The patient had a normal platelet count and no bleeding events on follow-up after three months upon discharge.</p><h3>Conclusion</h3><p dir="ltr">Eptifibatide, a glycoprotein IIa/IIIb inhibitor used in the management of acute coronary syndrome, can induce acute, profound thrombocytopenia that can have significant morbidity in patients. This case highlights this relatively rare side effect and the importance of monitoring blood counts and observing for any signs of bleeding or thrombosis that might occur in such patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1097/md.0000000000028243" target="_blank">https://dx.doi.org/10.1097/md.0000000000028243</a></p>2022-10-21T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1097/md.0000000000028243https://figshare.com/articles/journal_contribution/Eptifibatide-induced_acute_profound_thrombocytopenia_A_case_report/29046263CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/290462632022-10-21T06:00:00Z |
| spellingShingle | Eptifibatide-induced acute profound thrombocytopenia: A case report Mohammed A. Alamin (14182297) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences acute coronary syndrome drug-induced thrombocytopenia eptifibatide glycoprotein IIa/IIIb inhibitors thrombocytopenia |
| status_str | publishedVersion |
| title | Eptifibatide-induced acute profound thrombocytopenia: A case report |
| title_full | Eptifibatide-induced acute profound thrombocytopenia: A case report |
| title_fullStr | Eptifibatide-induced acute profound thrombocytopenia: A case report |
| title_full_unstemmed | Eptifibatide-induced acute profound thrombocytopenia: A case report |
| title_short | Eptifibatide-induced acute profound thrombocytopenia: A case report |
| title_sort | Eptifibatide-induced acute profound thrombocytopenia: A case report |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences acute coronary syndrome drug-induced thrombocytopenia eptifibatide glycoprotein IIa/IIIb inhibitors thrombocytopenia |